ARTICLE | Clinical News
FDA accepts NDA for Insys' buprenorphine sublingual spray
December 8, 2017 4:20 AM UTC
Insys Therapeutics Inc. (NASDAQ:INSY) said FDA accepted for review an NDA for the company’s buprenorphine sublingual spray to manage moderate to severe acute pain. The PDUFA date is July 28, 2018...
BCIQ Company Profiles